NanoPhoria is a preclinical-stage biotechnology company that develops next-generation cardiovascular treatments for patients suffering from conditions such as Heart Failure with Reduced Ejection Fraction (HFrEF). The company utilizes a proprietary inhaled Nano-in-Micro drug delivery platform based on inorganic Calcium Phosphate nanoparticles to enable precise, tissue-directed treatment.
Subscribe to see NanoPhoria’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
NanoPhoria is a biotech company headquartered in Italy. Its most recent funding round, Series A, raised $90.3M in October 2025. Xcout tracks 6 named people at NanoPhoria, including Dr Suman Shirodkar (chair).
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $90.3M | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of NanoPhoria's closest competitors — see the full list of competitors and alternatives →
Faraday Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the prevention of heart failure. The company has ceased operations and is in the process of winding down its business in accordance with applicable law.
Corteria Pharmaceuticals is a privately held biopharmaceutical company based in Paris, France, focused on developing first-in-class drugs for indications with high unmet medical need, particularly heart failure.
Imbria Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing novel cardiovascular therapies.
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the development of products to address pulmonary hypertension related to interstitial lung disease.
Pahr Therapeutics, Inc. is a biotechnology company focused on developing new treatments for pulmonary arterial hypertension (PAH). The company recently raised $14 million in seed funding to support its therapeutic development efforts.
Phoreus Biotechnology, Inc. is a privately held biotechnology company founded in 2018 and headquartered in Olathe, Kansas. The company specializes in the development of proprietary nanocarriers for targeted drug delivery and enhanced treatments.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about NanoPhoria? Suggest a correction · Work at NanoPhoria? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.